跳到正文
原文
Eric Topol· @EricTopol · X·· 26 天前精选AI 评分75
AI 导读

Eric Topol 引用 STAT 报道称,术后转移性黑色素瘤患者接受个体化 mRNA 新抗原疫苗后,2 年死亡率由 82% 降至 70%,复发率降低 42%。相关数据来自 Moderna 与默沙东的癌症疫苗 intismeran,在 ESMO 上公布。

推荐理由

材料给出术后转移性黑色素瘤个体化mRNA新抗原疫苗与对照组的2年死亡率和复发率对比数据。

正文

How to improve outcomes in patients with metastatic melanoma post-surgical resection, and specifically, vs controls:
—Reduce 2-year mortality from 82 to 70%
—Reduce recurrence by 42%
Treat with a personalized mRNA neoantigen vaccine
@statnews @adamfeuerstein
https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/?utm_campaign=daily_recap&utm_medium=email&_hsenc=p2ANqtz-_p0yydjfDz60pz_9XxOdG6QzlEEJxFK5gX5El7J-cSYBO_Jh57ioYGHylNtcGF_6Yol71vF-b6cFJH8h1J-plSbidetw&_hsmi=445602838&utm_content=445602838&utm_source=hs_email

来源:Eric Topol · x.com